🟢 Recruiting
Phase 2
💊 Investigational Drug / Biologic
NCT07175051
Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin
📍 University of Illinois Chicago, Sickle Cell Center — Chicago, Illinois
View Study & Checklist ➔